In the first session of the ACCC Knowledge Series, Optimizing Patient Outcomes with ADCs in Gynecologic Malignancies, Marilyn Huang, MD, MS, and Premal H. Thaker, MD, review the application of antibody-drug conjugates in gynecologic cancers, their adverse events, and mitigation strategies.
In the second session of the 2-part ACCC Knowledge Series, Optimizing Patient Outcomes with ADCs in Gynecologic Malignancies, Cynthia Ryan, PharmD, BCPS, reviews best practices for monitoring and managing adverse events with antibody-drug conjugates for gynecologic malignancies.
Learning objectives:
- Understand current indications for ADCs in gynecologic malignancies and future ADCs in development
- Use clinical data on ADCs to inform treatment decisions across gynecologic cancer types
- Identify and manage common adverse events associated with ADCs.